Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

37,962 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Drug conjugate-based anticancer therapy - Current status and perspectives.
Yang Y, Wang S, Ma P, Jiang Y, Cheng K, Yu Y, Jiang N, Miao H, Tang Q, Liu F, Zha Y, Li N. Yang Y, et al. Among authors: yu y. Cancer Lett. 2023 Jan 1;552:215969. doi: 10.1016/j.canlet.2022.215969. Epub 2022 Oct 22. Cancer Lett. 2023. PMID: 36279982 Free article. Review.
Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC.
Gao S, Li N, Gao S, Xue Q, Ying J, Wang S, Tao X, Zhao J, Mao Y, Wang B, Shao K, Lei W, Wang D, Lv F, Zhao L, Zhang F, Zhao Z, Su K, Tan F, Gao Y, Sun N, Wu D, Yu Y, Ling Y, Wang Z, Duan C, Tang W, Zhang L, He S, Wu N, Wang J, He J. Gao S, et al. Among authors: yu y. J Thorac Oncol. 2020 May;15(5):816-826. doi: 10.1016/j.jtho.2020.01.017. Epub 2020 Feb 6. J Thorac Oncol. 2020. PMID: 32036071 Free article. Clinical Trial.
Comprehensive Genomic Profiling of Rare Tumors: Routes to Targeted Therapies.
Wang S, Chen R, Tang Y, Yu Y, Fang Y, Huang H, Wu D, Fang H, Bai Y, Sun C, Yu A, Fan Q, Gu D, Yi X, Li N. Wang S, et al. Among authors: yu a, yu y. Front Oncol. 2020 Apr 21;10:536. doi: 10.3389/fonc.2020.00536. eCollection 2020. Front Oncol. 2020. PMID: 32373528 Free PMC article.
Clinical development of immuno-oncology in China.
Wu DW, Huang HY, Tang Y, Zhao Y, Yang ZM, Wang J, Wang SH, Yu Y, Fang Y, Fang H, Bai Y, Sun C, Fan Q, Yu AQ, Wang HL, Du CX, Chen K, Huang MD, Zhang Y, Li N, Xu BH, Sun Y, He J. Wu DW, et al. Among authors: yu aq, yu y. Lancet Oncol. 2020 Aug;21(8):1013-1016. doi: 10.1016/S1470-2045(20)30329-6. Lancet Oncol. 2020. PMID: 32758460 No abstract available.
The Landscape of Cell and Gene Therapies for Solid Tumors.
Wang S, Sun F, Huang H, Chen K, Li QJ, Zhang L, Wang E, Wang C, Zhang H, Yuan AQ, Chen B, Deng T, Liu Y, Sun J, Liu D, Yu Y, Fang Y, Jiang N, Wu D, Fang H, Bai Y, Xing S, Ni Y, Fan Q, Yu A, Sun C, Tang Y, Li N, Xu B, He J. Wang S, et al. Among authors: yu a, yu y. Cancer Cell. 2021 Jan 11;39(1):7-8. doi: 10.1016/j.ccell.2020.12.005. Cancer Cell. 2021. PMID: 33434513 Free article. No abstract available.
Pharmacoeconomic Evaluation of Cancer Biosimilars Worldwide: A Systematic Review.
Huang HY, Liu CC, Yu Y, Wang L, Wu DW, Guo LW, Wang SH, Fang H, Bai Y, Fang Y, Fan Q, Sun C, Wu Y, Shi JF, Ma F, Tang Y, Dai M, Li N. Huang HY, et al. Among authors: yu y. Front Pharmacol. 2020 Nov 12;11:572569. doi: 10.3389/fphar.2020.572569. eCollection 2020. Front Pharmacol. 2020. PMID: 33536905 Free PMC article. Review.
Platform study of genotyping-guided precision medicine for rare solid tumours: a study protocol for a phase II, non-randomised, 18-month, open-label, multiarm, single-centre clinical trial testing the safety and efficacy of multiple Chinese-approved targeted drugs and PD-1 inhibitors in the treatment of metastatic rare tumours.
Wang S, Huang HY, Wu D, Fang H, Ying J, Bai Y, Yu Y, Fang Y, Jiang N, Sun C, Yu A, Fan Q, Xing S, Ni Y, Zhang W, Wu C, Ji X, Wang H, Guo Y, Tang Q, Wang Y, Tang Y, Li N. Wang S, et al. Among authors: yu a, yu y. BMJ Open. 2021 Jun 3;11(6):e044543. doi: 10.1136/bmjopen-2020-044543. BMJ Open. 2021. PMID: 34083331 Free PMC article.
37,962 results
You have reached the last available page of results. Please see the User Guide for more information.